Literature DB >> 10613621

Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects.

X P Qin1, H G Xie, W Wang, N He, S L Huang, Z H Xu, D S Ou-Yang, Y J Wang, H H Zhou.   

Abstract

OBJECTIVE: To determine whether the gene dosage of CYP2C19 affects the metabolism of diazepam and desmethyldiazepam in healthy Chinese subjects. SUBJECTS AND METHODS: Eighteen unrelated adult men were recruited for the study from a total of 101 healthy Chinese volunteers who had been screened for CYP2C19 phenotype and genotype. All subjects received a single oral dose (5 mg) of diazepam, and the pharmacokinetics of diazepam and desmethyldiazepam were compared in six ml homozygotes (ml/ml), six ml heterozygotes (wt/ml), and six wild-type homozygotes (wt/wt).
RESULTS: The plasma elimination half-life values of diazepam (84.0 +/- 13.7 hours) and desmethyldiazepam (176.0 +/- 28.9 hours) in subjects of ml/ml were significantly longer than those (62.9 +/- 9.8 hours for diazepam; 132.1 +/- 24.9 hours for desmethyldiazepam; both P < .01) in subjects of wt/ml or those (20.0 +/- 10.8 hours for diazepam; 99.2.+/- 21.7 hours for desmethyldiazepam; both P < .01) in subjects of wt/wt. A significant difference in the corresponding half-life values existed between the wt/ml and wt/wt subjects (P < .01). As expected, the slowest mean clearance of diazepam was observed in the ml/ml subjects (2.8 +/- 0.9 mL/min) and the fastest in the wt/wt subjects (19.5 +/- 9.8 mL/min), with the wt/ml heterozygotes having an intermediate value (7.2 +/- 2.6 mL/min).
CONCLUSION: The presence of a single-nucleotide polymorphism (G681A) of the CYP2C19 gene cosegregates with the impaired metabolism of diazepam and desmethyldiazepam among Chinese subjects in a gene-dosage effect manner.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613621     DOI: 10.1016/S0009-9236(99)90075-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

3.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

4.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.

Authors:  R Michael Baldwin; Staffan Ohlsson; Rasmus Steen Pedersen; Jessica Mwinyi; Magnus Ingelman-Sundberg; Erik Eliasson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

Review 5.  [Pharmacogenetics. Clinical relevance in anesthsiology].

Authors:  E M Zeidler; A E Goetz; C Zöllner
Journal:  Anaesthesist       Date:  2013-11       Impact factor: 1.041

6.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

7.  Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

8.  Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.

Authors:  Manu Jose; Jayanthi Mathaiyan; Shivanand Kattimani; Surendiran Adithan; Adithan Chandrasekaran
Journal:  Eur J Clin Pharmacol       Date:  2016-04-20       Impact factor: 2.953

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Nathalie Bleyzac; Johanna Berry; Fannie Clavel-Grabit; Michel Tod
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.